+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Lung Cancer Screening Market, Size, Global Forecast 2023-2028, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis

  • PDF Icon

    Report

  • 390 Pages
  • September 2023
  • Region: Global
  • Renub Research
  • ID: 5521704
Lung Cancer Screening Market size is projected to reach US$ 4.36 Billion by 2028, according to the report. Cancer these days is one of the most common causes of mortality worldwide. Lung cancer is the second most common type of cancer according to World Health Organization (WHO). The number one objective of lung cancers screening is to discover the presence of lung cancers in its earliest possible phase. This screening is usually encouraged for older people with records of long-term smoking, who are currently asymptomatic for lung cancers. Healthcare providers employ low-dose automated tomography (LDCT) scans or X-rays as screening equipment. There is a growing worldwide cognizance of the significance of early detection, which has led to an expanded demand for lung cancers screening.

According to the Lung Cancer Alliance, generally there is 5-year survival rate for lung cancers a significant decline because the disease progresses from stage 1 (with a survival charge starting from 68% to 92%) to stage 4 (with a survival fee as low as 0% to 10%). Growing number of lung cancers cases worldwide is one of the most essential drivers of the lung cancers screening market.

Lung cancer screening market is projected to grow at a CAGR of 7.34% from 2022 to 2028

The worldwide lung cancers screening market is experiencing sizeable growth due to the growing populace of people who are smokers & tobacco user and improvements in lung cancers screening technology. According to the FDA (Food and Drug Administration), about 2.55 million students used tobacco product in 2021 and according to Centers for Disease Control and Prevention (CDC), almost thirteen out of each one hundred adults' age 18 and older in the United States had been cigarette smokers in 2020. Additionally, the growing occurrence of lung cancer is a leading contributing component to the increasing demand for lung cancer screening.

In Australia, lung cancer is the most dangerous kind of cancer, which accounts for a significant percentage of fatality cases. According to the Cancer Australia 2023, early detection of lung cancer is crucial for increasing survival rates. Furthermore, newly developed screening software tries to identify lung tumors in their earliest level, when therapy is more likely to be successful. In July 2021, the Department of Health and Aged Care and Cancer Australia implemented lung cancer screening campaign in Australia.

Furthermore, the global lung cancer screening market is growing due to numerous elements, along with improved utilization of low-dose computed tomography by healthcare specialists. The growing consciousness of innovative and cost-effective lung cancer screening techniques in developing nations like India and China is contributing to the growth of the market. Prominent Market players are pursuing mergers & acquisitions with healthcare establishments to elevate awareness of lung cancer among the population. For instance, Baptist Health South Florida's Miami Cancer Institute (MCI) and Nuance Communications, Inc. collaborated to set up a lung cancer screening program that conducts imaging tests for the early analysis and effective treatment of the lung cancer disease. The lung cancer screening market was valued at US$ 2.85 billion in 2022.

Non-Small Cell Lung Cancer (NSCLC) accounted for largest revenue share in the lung cancers screening market

By Cancer Type, Lung cancer screening market is segmented into Non-Small-cellular Lung Cancer Diagnostics and Small-cellular Lung Cancer Diagnostics. Non-small cell lung cancer (NSCLC) has emerged as the dominant driver of revenue in the lung cancer screening market. This type of lung cancer, recognized for its relative insensitivity to chemotherapy and radiotherapy, has claimed the largest percentage of monetary resources committed to screening and treatment. Its incidence and difficult nature have propelled it to the forefront of research and funding within the area. The vast sales contribution from NSCLC underscores the urgent need for continued advancements in early detection techniques and progressive therapeutic techniques to fight this formidable disease, ultimately improving affected persons consequences and survival costs.

Hospitals & clinics section accounted for largest market in the Lung cancers screening market

By End User, Lung cancers screening market is divided into Hospitals & Clinics, Diagnostic Centers, Research Institute and Others. The hospitals & clinics section accounted for largest Market. Hospitals and clinics, equipped with advance diagnostic tools and medical expertise, are at the leading front conducting screenings, diagnosing capability cases, and initiating timely interventions. This substantial market presence signifies the believe patients and healthcare provider place in these facilities for accurate and comprehensive lung cancer screening services. As the primary interface between patients and medical solutions, hospitals and clinics are instrumental in shaping the trajectory of lung cancers management and improving patient outcomes.

The diagnostic centers sector accounted for fastest developing market percentage all through forecast year. For older peoples, diagnostic facilities are an ideal alternative considering the fact that they offer individualized treatment and reduce the need for repeated health facility visits. In addition to having more manipulated over scheduling of methods, outpatient surgical procedure centers may be 45%-60% much less steeply-priced than hospitals, which advantages patients, insurance, and taxpayers similarly. As a result, compared to sudden sanatorium activities, very few surgical procedures may additionally want to be postponed or rescheduled.

China lung cancer market is expected to witness significant growth due to the rise in prevalence of lung cancer and increase in demand for early and accurate diagnosis

By Country, Lung cancers screening market is break up into United States, Canada, Mexico, Germany, United Kingdom, France, Italy, Spain, Netherlands, Switzerland, China, Japan, India, South Korea, Australia, Brazil, Argentina, Saudi Arabia, U.A.E, South Africa and Rest of the World. China has emerged as a dominant market in the global lung cancers screening market due to its amplified recognition of the advantages associated with early-stage lung cancer screening. With a large populace, China's huge reach enables a wider variety of screenings, raising huge revenue possibilities. Leveraging superior screening technologies and progressive devices, the nation has fortified its role by presenting accurate diagnostics. This dominance stems from heightened focus campaigns that spotlight the advantages of early-degree screening, fostering a proactive method to healthcare. Government assist and innovative guidelines have catalyzed this growth, nurturing an environment conducive to scientific innovation and infrastructure development. China's ascendancy underscores its pivotal function in reshaping the panorama of lung cancer screening, sponsored via a strong confluence of technology, cognizance, and strategic healthcare initiatives.

Key Players

Some important players operating in the lung cancers screening market report are lluminaInc, Abbott Laboratories, Thermo Fisher Scientific Inc, QIAGEN N.V., Roche Holding AG and Medtronic percent.

In June 2022, Royal Philips teamed up with Biodesix, Inc. to include the results of Biodesix’s Nodify Lung blood-based totally lung nodule danger evaluation trying out into Philips Lung Cancer Orchestrator lung cancer affected person management machine.

In August 2022, Intelerad Medical Systems acquired PenRad Technologies, Inc., a software company for boosting breast imaging and lung screening productiveness. The acquisition has elevated Intelerad’s product offerings for mammography and lung analytics, optimizing workflow for radiologists and boosting patient fitness outcomes.

The latest report “Lung Cancer Screening Market, Global Forecast By Cancer Type (Non-Small-cell Lung Cancer Diagnostics and Small-cell Lung Cancer Diagnostics), End-User (Hospitals & Clinics, Diagnostic Centers, Research Institute and Others), Country (United States, Canada, Mexico, Germany, United Kingdom, France, Italy, Spain, Netherlands, Switzerland, China, Japan, India, South Korea, Australia, Brazil, Argentina, Saudi Arabia, U.A.E, South Africa and Rest of the World), Companies (llumina, Inc., Abbott Laboratories, Thermo Fisher Scientific, Inc, QIAGEN N.V., Roche Holding AG & Medtronic Plc)” provides a detailed analysis of Lung Cancer Screening Industry.

Cancer Type - Lung Cancer Screening Market has been covered from 2 viewpoints:

1. Non-Small-cell Lung Cancer Diagnostics
2. Small-cell Lung Cancer Diagnostics

End-User - Lung Cancer Screening Market has been covered from 4 viewpoints:

1. Hospitals & Clinics
2. Diagnostic Centers
3. Research Institute
4. Others

Countries - Lung Cancer Screening Market has been covered from 21 viewpoints:

1 North America

1.1 United States
1.2 Canada
1.3 Mexico

2 Europe

2.1 Germany
2.2 United Kingdom
2.3 France
2.4 Italy
2.5 Spain
2.6 Netherlands
2.7 Switzerland

3 Asia Pacific

3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Australia

4 South America

4.1 Brazil
4.2 Argentina

5 Middle East & Africa

5.1 Saudi Arabia
5.2 U.A.E
5.3 South Africa

6 Rest of the World

Company Insights:

  • Overviews
  • Recent Development
  • Revenue

Company Analysis:

1. llumina, Inc.
2. Abbott Laboratories
3. Thermo Fisher Scientific, Inc
4. QIAGEN N.V.
5. Roche Holding AG.
6. Medtronic plc

Table of Contents

1. Introduction2. Research & Methodology3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Global Lung Cancer Screening Market and Volume Analysis
5.1 Market
5.2 Volume
6. Market Share - Global Lung Cancer Screening
6.1 By Cancer Type
6.2 By End User
6.3 By Country
7. Cancer Type -Global Lung Cancer Screening Market
7.1 Non-Small-cell Lung Cancer (NSCLC)
7.2 Small-cell Lung Cancer
8. End User - Global Lung Cancer Screening Market
8.1 Hospitals & Clinics
8.2 Diagnostic Centers
8.3 Research Institute
8.4 Others
9. North America - Lung Cancer Statistics
9.1 United States
9.1.1 Lung Cancer Screening Market
9.1.2 Lung Cancer Screening Numbers
9.1.3 Lung Cancer Cases
9.1.4 Lung Cancer Deaths
9.2 Canada
9.2.1 Lung Cancer Screening Market
9.2.2 Lung Cancer Screening Numbers
9.2.3 Lung Cancer Cases
9.2.4 Lung Cancer Deaths
9.3 Mexico
9.3.1 Lung Cancer Screening Market
9.3.2 Lung Cancer Screening Numbers
9.3.3 Lung Cancer Cases
9.3.4 Lung Cancer Deaths
10. Europe - Lung Cancer Statistics
10.1 Germany
10.1.1 Lung Cancer Screening Market
10.1.2 Lung Cancer Screening Numbers
10.1.3 Lung Cancer Cases
10.1.4 Lung Cancer Deaths
10.2 United Kingdom
10.2.1 Lung Cancer Screening Market
10.2.2 Lung Cancer Screening Numbers
10.2.3 Lung Cancer Cases
10.2.4 Lung Cancer Deaths
10.3 France
10.3.1 Lung Cancer Screening Market
10.3.2 Lung Cancer Screening Numbers
10.3.3 Lung Cancer Cases
10.3.4 Lung Cancer Deaths
10.4 Italy
10.4.1 Lung Cancer Screening Market
10.4.2 Lung Cancer Screening Numbers
10.4.3 Lung Cancer Cases
10.4.4 Lung Cancer Deaths
10.5 Spain
10.5.1 Lung Cancer Screening Market
10.5.2 Lung Cancer Screening Numbers
10.5.3 Lung Cancer Cases
10.5.4 Lung Cancer Deaths
10.6 Netherlands
10.6.1 Lung Cancer Screening Market
10.6.2 Lung Cancer Screening Numbers
10.6.3 Lung Cancer Cases
10.6.4 Lung Cancer Deaths
10.7 Switzerland
10.7.1 Lung Cancer Screening Market
10.7.2 Lung Cancer Screening Numbers
10.7.3 Lung Cancer Cases
10.7.4 Lung Cancer Deaths
11. Asia - Lung Cancer Statistics
11.1 China
11.1.1 Lung Cancer Screening Market
11.1.2 Lung Cancer Screening Numbers
11.1.3 Lung Cancer Cases
11.1.4 Lung Cancer Deaths
11.2 Japan
11.2.1 Lung Cancer Screening Market
11.2.2 Lung Cancer Screening Numbers
11.2.3 Lung Cancer Cases
11.2.4 Lung Cancer Deaths
11.3 India
11.3.1 Lung Cancer Screening Market
11.3.2 Lung Cancer Screening Numbers
11.3.3 Lung Cancer Cases
11.3.4 Lung Cancer Deaths
11.4 South Korea
11.4.1 Lung Cancer Screening Market
11.4.2 Lung Cancer Screening Numbers
11.4.3 Lung Cancer Cases
11.4.4 Lung Cancer Deaths
11.5 Australia
11.5.1 Lung Cancer Screening Market
11.5.2 Lung Cancer Screening Numbers
11.5.3 Lung Cancer Cases
11.5.4 Lung Cancer Deaths
12. Latin America - Lung Cancer Statistics
12.1 Brazil
12.1.1 Lung Cancer Screening Market
12.1.2 Lung Cancer Screening Numbers
12.1.3 Lung Cancer Cases
12.1.4 Lung Cancer Deaths
12.2 Argentina
12.2.1 Lung Cancer Screening Market
12.2.2 Lung Cancer Screening Numbers
12.2.3 Lung Cancer Cases
12.2.4 Lung Cancer Deaths
13. Middle East & Africa - Lung Cancer Statistics
13.1 Saudi Arabia
13.1.1 Lung Cancer Screening Market
13.1.2 Lung Cancer Screening Numbers
13.1.3 Lung Cancer Cases
13.1.4 Lung Cancer Deaths
13.2 U.A.E
13.2.1 Lung Cancer Screening Market
13.2.2 Lung Cancer Screening Numbers
13.2.3 Lung Cancer Cases
13.2.4 Lung Cancer Deaths
13.3 South Africa
13.3.1 Lung Cancer Screening Market
13.3.2 Lung Cancer Screening Numbers
13.3.3 Lung Cancer Cases
13.3.4 Lung Cancer Deaths
14. Porter’s Five Forces
14.1 Bargaining Power of Buyers
14.2 Bargaining Power of Suppliers
14.3 Degree of Rivalry
14.4 Threat of New Entrants
14.5 Threat of Substitutes
15. SWOT Analysis
15.1 Strength
15.2 Weakness
15.3 Opportunity
15.4 Threat
16. Company Analysis
16.1 llumina, Inc.
16.1.1 Overview
16.1.2 Recent Development
16.1.3 Revenue
16.2 Abbott Laboratories
16.2.1 Overview
16.2.2 Recent Development
16.2.3 Revenue
16.3 Thermo Fisher Scientific, Inc
16.3.1 Overview
16.3.2 Recent Development
16.3.3 Revenue
16.4 QIAGEN N.V.
16.4.1 Overview
16.4.2 Recent Development
16.4.3 Revenue
16.5 Roche Holding AG.
16.5.1 Overview
16.5.2 Recent Development
16.5.3 Revenue
16.6 Medtronic plc
16.6.1 Overview
16.6.2 Recent Development
16.6.3 Revenues
List of Figures
Figure 01: Global Lung Cancer Screening Market (Million US$), 2018-2022
Figure 02: Forecast for - Global Lung Cancer Screening Market (Million US$), 2023-2028
Figure 03: Global Lung Cancer Screening Volume (Thousand), 2018-2022
Figure 04: Forecast for - Global Lung Cancer Screening Volume (Thousand), 2023-2028
Figure 05: Cancer Type - Non-Small-cell Lung Cancer (NSCLC) Market (Million US$), 2018-2022
Figure 06: Cancer Type - Forecast for Non-Small-cell Lung Cancer (NSCLC) Market (Million US$), 2023-2028
Figure 07: Cancer Type - Small-cell Lung Cancer Market (Million US$), 2018-2022
Figure 08: Cancer Type - Forecast for Small-cell Lung Cancer Market (Million US$), 2023-2028
Figure 09: End Users - Hospitals & Clinics Market (Million US$), 2018-2022
Figure 10: End Users - Forecast for Hospitals & Clinics Market (Million US$), 2023-2028
Figure 11: End Users - Diagnostic Centers Market (Million US$), 2018-2022
Figure 12: End Users - Forecast for Diagnostic Centers Market (Million US$), 2023-2028
Figure 13: End Users - Research Institute Market (Million US$), 2018-2022
Figure 14: End Users - Forecast for Research Institute Market (Million US$), 2023-2028
Figure 15: End Users - Others Market (Million US$), 2018-2022
Figure 16: End Users - Forecast for Others Market (Million US$), 2023-2028
Figure 17: United States - Lung Cancer Screening Market (Million US$), 2018-2022
Figure 18: United States - Forecast for Lung Cancer Screening Market (Million US$), 2023-2028
Figure 19: United States - Lung Cancer Screening Numbers (Thousand), 2018-2022
Figure 20: United States - Forecast for Lung Cancer Screening Numbers (Thousand), 2023-2028
Figure 21: United States - Lung Cancer Cases (Number), 2018-2022
Figure 22: United States - Forecast for Lung Cancer Cases (Number), 2023-2028
Figure 23: United States - Lung Cancer Deaths (Number), 2018-2022
Figure 24: United States - Forecast for Lung Cancer Deaths (Number), 2023-2028
Figure 25: Canada - Lung Cancer Screening Market (Million US$), 2018-2022
Figure 26: Canada - Forecast for Lung Cancer Screening Market (Million US$), 2023-2028
Figure 27: Canada - Lung Cancer Screening Numbers (Thousand), 2018-2022
Figure 28: Canada - Forecast for Lung Cancer Screening Numbers (Thousand), 2023-2028
Figure 29: Canada - Lung Cancer Cases (Number), 2018-2022
Figure 30: Canada - Forecast for Lung Cancer Cases (Number), 2023-2028
Figure 31: Canada - Lung Cancer Deaths (Number), 2018-2022
Figure 32: Canada - Forecast for Lung Cancer Deaths (Number), 2023-2028
Figure 33: Mexico - Lung Cancer Screening Market (Million US$), 2018-2022
Figure 34: Mexico - Forecast for Lung Cancer Screening Market (Million US$), 2023-2028
Figure 35: Mexico - Lung Cancer Screening Numbers (Thousand), 2018-2022
Figure 36: Mexico - Forecast for Lung Cancer Screening Numbers (Thousand), 2023-2028
Figure 37: Mexico - Lung Cancer Cases (Number), 2018-2022
Figure 38: Mexico - Forecast for Lung Cancer Cases (Number), 2023-2028
Figure 39: Mexico - Lung Cancer Deaths (Number), 2018-2022
Figure 40: Mexico - Forecast for Lung Cancer Deaths (Number), 2023-2028
Figure 41: Germany - Lung Cancer Screening Market (Million US$), 2018-2022
Figure 42: Germany - Forecast for Lung Cancer Screening Market (Million US$), 2023-2028
Figure 43: Germany - Lung Cancer Screening Numbers (Thousand), 2018-2022
Figure 44: Germany - Forecast for Lung Cancer Screening Numbers (Thousand), 2023-2028
Figure 45: Germany - Lung Cancer Cases (Number), 2018-2022
Figure 46: Germany - Forecast for Lung Cancer Cases (Number), 2023-2028
Figure 47: Germany - Lung Cancer Deaths (Number), 2018-2021
Figure 48: Germany - Forecast for Lung Cancer Deaths (Number), 2023-2028
Figure 49: United Kingdom - Lung Cancer Screening Market (Million US$), 2018-2022
Figure 50: United Kingdom - Forecast for Lung Cancer Screening Market (Million US$), 2023-2028
Figure 51: United Kingdom - Lung Cancer Screening Numbers (Thousand), 2018-2022
Figure 52: United Kingdom - Forecast for Lung Cancer Screening Numbers (Thousand), 2023-2028
Figure 53: United Kingdom - Lung Cancer Cases (Number), 2018-2022
Figure 54: United Kingdom - Forecast for Lung Cancer Cases (Number), 2023-2028
Figure 55: United Kingdom - Lung Cancer Deaths (Number), 2018-2022
Figure 56: United Kingdom - Forecast for Lung Cancer Deaths (Number), 2023-2028
Figure 57: France - Lung Cancer Screening Market (Million US$), 2018-2022
Figure 58: France - Forecast for Lung Cancer Screening Market (Million US$), 2023-2028
Figure 59: France - Lung Cancer Screening Numbers (Thousand), 2018-2022
Figure 60: France - Forecast for Lung Cancer Screening Numbers (Thousand), 2023-2028
Figure 61: France - Lung Cancer Cases (Number), 2018-2022
Figure 62: France - Forecast for Lung Cancer Cases (Number), 2023-2028
Figure 63: France - Lung Cancer Deaths (Number), 2018-2022
Figure 64: France - Forecast for Lung Cancer Deaths (Number), 2023-2028
Figure 65: Italy - Lung Cancer Screening Market (Million US$), 2018-2022
Figure 66: Italy - Forecast for Lung Cancer Screening Market (Million US$), 2023-2028
Figure 67: Italy - Lung Cancer Screening Numbers (Thousand), 2018-2022
Figure 68: Italy - Forecast for Lung Cancer Screening Numbers (Thousand), 2023-2028
Figure 69: Italy - Lung Cancer Cases (Number), 2018-2022
Figure 70: Italy - Forecast for Lung Cancer Cases (Number), 2023-2028
Figure 71: Italy - Lung Cancer Deaths (Number), 2018-2021
Figure 72: Italy - Forecast for Lung Cancer Deaths (Number), 2023-2028
Figure 73: Spain - Lung Cancer Screening Market (Million US$), 2018-2022
Figure 74: Spain - Forecast for Lung Cancer Screening Market (Million US$), 2023-2028
Figure 75: Spain - Lung Cancer Screening Numbers (Thousand), 2018-2022
Figure 76: Spain - Forecast for Lung Cancer Screening Numbers (Thousand), 2023-2028
Figure 77: Spain - Lung Cancer Cases (Number), 2018-2022
Figure 78: Spain - Forecast for Lung Cancer Cases (Number), 2023-2028
Figure 79: Spain - Lung Cancer Deaths (Number), 2018-2022
Figure 80: Spain - Forecast for Lung Cancer Deaths (Number), 2023-2028
Figure 81: Netherlands - Lung Cancer Screening Market (Million US$), 2018-2022
Figure 82: Netherlands - Forecast for Lung Cancer Screening Market (Million US$), 2023-2028
Figure 83: Netherlands - Lung Cancer Screening Numbers (Thousand), 2018-2022
Figure 84: Netherlands - Forecast for Lung Cancer Screening Numbers (Thousand), 2023-2028
Figure 85: Netherlands - Lung Cancer Cases (Number), 2018-2022
Figure 86: Netherlands - Forecast for Lung Cancer Cases (Number), 2023-2028
Figure 87: Netherlands - Lung Cancer Deaths (Number), 2018-2022
Figure 88: Netherlands - Forecast for Lung Cancer Deaths (Number), 2023-2028
Figure 89: Switzerland - Lung Cancer Screening Market (Million US$), 2018-2022
Figure 90: Switzerland - Forecast for Lung Cancer Screening Market (Million US$), 2023-2028
Figure 91: Switzerland - Lung Cancer Screening Numbers (Thousand), 2018-2022
Figure 92: Switzerland - Forecast for Lung Cancer Screening Numbers (Thousand), 2023-2028
Figure 93: Switzerland - Lung Cancer Cases (Number), 2018-2022
Figure 94: Switzerland - Forecast for Lung Cancer Cases (Number), 2023-2028
Figure 95: Switzerland - Lung Cancer Deaths (Number), 2018-2022
Figure 96: Switzerland - Forecast for Lung Cancer Deaths (Number), 2023-2028
Figure 97: China - Lung Cancer Screening Market (Million US$), 2018-2022
Figure 98: China - Forecast for Lung Cancer Screening Market (Million US$), 2023-2028
Figure 99: China - Lung Cancer Screening Numbers (Thousand), 2018-2022
Figure 100: China - Forecast for Lung Cancer Screening Numbers (Thousand), 2023-2028
Figure 101: China - Lung Cancer Cases (Number), 2018-2022
Figure 102: China - Forecast for Lung Cancer Cases (Number), 2023-2028
Figure 103: China - Lung Cancer Deaths (Number), 2018-2022
Figure 104: China - Forecast for Lung Cancer Deaths (Number), 2023-2028
Figure 105: Japan - Lung Cancer Screening Market (Million US$), 2018-2022
Figure 106: Japan - Forecast for Lung Cancer Screening Market (Million US$), 2023-2028
Figure 107: Japan - Lung Cancer Screening Numbers (Thousand), 2018-2022
Figure 108: Japan - Forecast for Lung Cancer Screening Numbers (Thousand), 2023-2028
Figure 109: Japan - Lung Cancer Cases (Number), 2018-2022
Figure 110: Japan - Forecast for Lung Cancer Cases (Number), 2023-2028
Figure 111: Japan - Lung Cancer Deaths (Number), 2018-2021
Figure 112: Japan - Forecast for Lung Cancer Deaths (Number), 2023-2028
Figure 113: India - Lung Cancer Screening Market (Million US$), 2018-2022
Figure 114: India - Forecast for Lung Cancer Screening Market (Million US$), 2023-2028
Figure 115: India - Lung Cancer Screening Numbers (Thousand), 2018-2022
Figure 116: India - Forecast for Lung Cancer Screening Numbers (Thousand), 2023-2028
Figure 117: India - Lung Cancer Cases (Number), 2018-2022
Figure 118: India - Forecast for Lung Cancer Cases (Number), 2023-2028
Figure 119: India - Lung Cancer Deaths (Number), 2018-2021
Figure 120: India - Forecast for Lung Cancer Deaths (Number), 2023-2028
Figure 121: South Korea - Lung Cancer Screening Market (Million US$), 2018-2022
Figure 122: South Korea - Forecast for Lung Cancer Screening Market (Million US$), 2023-2028
Figure 123: South Korea - Lung Cancer Screening Numbers (Thousand), 2018-2022
Figure 124: South Korea - Forecast for Lung Cancer Screening Numbers (Thousand), 2023-2028
Figure 125: South Korea - Lung Cancer Cases (Number), 2018-2022
Figure 126: South Korea - Forecast for Lung Cancer Cases (Number), 2023-2028
Figure 127: South Korea - Lung Cancer Deaths (Number), 2018-2022
Figure 128: South Korea - Forecast for Lung Cancer Deaths (Number), 2023-2028
Figure 129: Australia - Lung Cancer Screening Market (Million US$), 2018-2022
Figure 130: Australia - Forecast for Lung Cancer Screening Market (Million US$), 2023-2028
Figure 131: Australia - Lung Cancer Screening Numbers (Thousand), 2018-2022
Figure 132: Australia - Forecast for Lung Cancer Screening Numbers (Thousand), 2023-2028
Figure 133: Australia - Lung Cancer Cases (Number), 2018-2022
Figure 134: Australia - Forecast for Lung Cancer Cases (Number), 2023-2028
Figure 135: Australia - Lung Cancer Deaths (Number), 2018-2021
Figure 136: Australia - Forecast for Lung Cancer Deaths (Number), 2023-2028
Figure 137: Brazil - Lung Cancer Screening Market (Million US$), 2018-2022
Figure 138: Brazil - Forecast for Lung Cancer Screening Market (Million US$), 2023-2028
Figure 139: Brazil - Lung Cancer Screening Numbers (Thousand), 2018-2022
Figure 140: Brazil - Forecast for Lung Cancer Screening Numbers (Thousand), 2023-2028
Figure 141: Brazil - Lung Cancer Cases (Number), 2018-2022
Figure 142: Brazil - Forecast for Lung Cancer Cases (Number), 2023-2028
Figure 143: Brazil - Lung Cancer Deaths (Number), 2018-2021
Figure 144: Brazil - Forecast for Lung Cancer Deaths (Number), 2023-2028
Figure 145: Argentina - Lung Cancer Screening Market (Million US$), 2018-2022
Figure 146: Argentina - Forecast for Lung Cancer Screening Market (Million US$), 2023-2028
Figure 147: Argentina - Lung Cancer Screening Numbers (Thousand), 2018-2022
Figure 148: Argentina - Forecast for Lung Cancer Screening Numbers (Thousand), 2023-2028
Figure 149: Argentina - Lung Cancer Cases (Number), 2018-2022
Figure 150: Argentina - Forecast for Lung Cancer Cases (Number), 2023-2028
Figure 151: Argentina - Lung Cancer Deaths (Number), 2018-2021
Figure 152: Argentina - Forecast for Lung Cancer Deaths (Number), 2023-2028
Figure 153: Saudi Arabia - Lung Cancer Screening Market (Million US$), 2018-2022
Figure 154: Saudi Arabia - Forecast for Lung Cancer Screening Market (Million US$), 2023-2028
Figure 155: Saudi Arabia - Lung Cancer Screening Numbers (Thousand), 2018-2022
Figure 156: Saudi Arabia - Forecast for Lung Cancer Screening Numbers (Thousand), 2023-2028
Figure 157: Saudi Arabia - Lung Cancer Cases (Number), 2018-2022
Figure 158: Saudi Arabia - Forecast for Lung Cancer Cases (Number), 2023-2028
Figure 159: Saudi Arabia - Lung Cancer Deaths (Number), 2018-2021
Figure 160: Saudi Arabia - Forecast for Lung Cancer Deaths (Number), 2023-2028
Figure 161: U.A.E - Lung Cancer Screening Market (Million US$), 2018-2022
Figure 162: U.A.E - Forecast for Lung Cancer Screening Market (Million US$), 2023-2028
Figure 163: U.A.E - Lung Cancer Screening Numbers (Thousand), 2018-2022
Figure 164: U.A.E - Forecast for Lung Cancer Screening Numbers (Thousand), 2023-2028
Figure 165: U.A.E - Lung Cancer Cases (Number), 2018-2022
Figure 166: U.A.E - Forecast for Lung Cancer Cases (Number), 2023-2028
Figure 167: U.A.E - Lung Cancer Deaths (Number), 2018-2021
Figure 168: U.A.E - Forecast for Lung Cancer Deaths (Number), 2023-2028
Figure 169: South Africa - Lung Cancer Screening Market (Million US$), 2018-2022
Figure 170: South Africa - Forecast for Lung Cancer Screening Market (Million US$), 2023-2028
Figure 171: South Africa - Lung Cancer Screening Numbers (Thousand), 2018-2022
Figure 172: South Africa - Forecast for Lung Cancer Screening Numbers (Thousand), 2023-2028
Figure 173: South Africa - Lung Cancer Cases (Number), 2018-2022
Figure 174: South Africa - Forecast for Lung Cancer Cases (Number), 2023-2028
Figure 175: South Africa - Lung Cancer Deaths (Number), 2018-2021
Figure 176: South Africa - Forecast for Lung Cancer Deaths (Number), 2023-2028
Figure 177: llumina, Inc. - Global Revenue (Million US$), 2018-2022
Figure 178: llumina, Inc. - Forecast for Global Revenue (Million US$), 2023-2028
Figure 179: Abbott Laboratories - Global Revenue (Million US$), 2018-2022
Figure 180: Abbott Laboratories - Forecast for Global Revenue (Million US$), 2023-2028
Figure 181: Thermo Fisher Scientific, Inc - Global Revenue (Million US$), 2018-2022
Figure 182: Thermo Fisher Scientific, Inc - Forecast for Global Revenue (Million US$), 2023-2028
Figure 183: QIAGEN N.V. - Global Revenue (Million US$), 2018-2022
Figure 184: QIAGEN N.V. - Forecast for Global Revenue (Million US$), 2023-2028
Figure 185: Roche Holding AG. - Global Revenue (Million US$), 2018-2022
Figure 186: Roche Holding AG. - Forecast for Global Revenue (Million US$), 2023-2028
Figure 187: Medtronic plc - Global Revenue (Million US$), 2018-2022
Figure 188: Medtronic plc - Forecast for Global Revenue (Million US$), 2023-2028
List of Tables
Table 01: Global - Lung Cancer Screening Market Share by Cancer Type (Percent), 2018-2022
Table 02: Global - Forecast for Lung Cancer Screening Market Share by Cancer Type (Percent), 2023-2028
Table 03: Global - Lung Cancer Screening Market Share by End User (Percent), 2018-2022
Table 04: Global - Forecast for Lung Cancer Screening Market Share by End User (Percent), 2023-2028
Table 05: Global - Lung Cancer Screening Market Share by Regions (Percent), 2018-2022
Table 06: Global - Forecast for Lung Cancer Screening Market Share by Regions (Percent), 2023-2028

Companies Mentioned

  • llumina, Inc.
  • Abbott Laboratories
  • Thermo Fisher Scientific, Inc
  • QIAGEN N.V.
  • Roche Holding AG.
  • Medtronic plc

Methodology

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Table Information